Evidence map›Paper›PMID 41255818›Full record

ArticleFrontiers in neuroscience2025

Deep learning-driven MRI for accurate brain volumetry in murine models of neurodegenerative diseases.

Arno Doelemeyer, Saurabh Vaishampayan, Stefan Zurbruegg, Frédéric Morvan, Giuseppe Locatelli, Derya R Shimshek, Nicolau Beckmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arno Doelemeyer *Novartis Biomedical Research, Basel, Switzerland.
Saurabh Vaishampayan *École Polytechnique Fédérale de Lausanne, School of Engineering, Lausanne, Switzerland.
Stefan ZurbrueggNovartis Biomedical Research, Basel, Switzerland.
Frédéric MorvanNovartis Biomedical Research, Basel, Switzerland.
Giuseppe LocatelliNovartis Biomedical Research, Basel, Switzerland.
Derya R ShimshekNovartis Biomedical Research, Basel, Switzerland.
Nicolau BeckmannNovartis Biomedical Research, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain atrophy as assessed by magnetic resonance imaging (MRI) is a key measure of neurodegeneration and a predictor of disability progression in Alzheimer's disease and multiple sclerosis (MS) patients. While MRI-based brain volumetry is valuable for analyzing neurodegeneration in murine models as well, achieving high spatial resolution at sufficient signal-to-noise ratio is challenging due to the small size of the mouse brain.

Indexed as

3R principlesamyotrophic lateral sclerosis (ALS)artificial intelligencedeep learningmagnetic resonance imaging (MRI)multiple sclerosis (MS)neurodegenerationvolumetry

Identifiers

PMID41255818
PMCPMC12620470

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.